Paromomycin
- Generic Name
- Paromomycin
- Brand Names
- Humatin
- Drug Type
- Small Molecule
- Chemical Formula
- C23H45N5O14
- CAS Number
- 7542-37-2
- Unique Ingredient Identifier
- 61JJC8N5ZK
- Background
An oligosaccharide antibiotic produced by various streptomyces. [PubChem]
- Indication
For the treatment of acute and chronic intestinal amebiasis (it is not effective in extraintestinal amebiasis). Also for the management of hepatic coma as adjunctive therapy.
- Associated Conditions
- Dientamoeba fragilis infection, Hepatic coma, Acute Intestinal amebiasis, Chronic Intestinal amebiasis
Treatment of Chronic Cryptosporidiosis in AIDS Patients
Not Applicable
Terminated
- Conditions
- CryptosporidiosisHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2016-12-14
- Target Recruit Count
- 16
- Registration Number
- NCT00001128
- Locations
- 🇺🇸
Pablo C. Okhuysen, Houston, Texas, United States
A Double-Blind, Placebo-Controlled Trial of Paromomycin for Treatment of Cryptosporidiosis in Patients With Advanced HIV Disease and CD4 Counts Under 150 Cells/mm3
Phase 2
Completed
- Conditions
- CryptosporidiosisHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 68
- Registration Number
- NCT00000771
- Locations
- 🇵🇷
Puerto Rico-AIDS CRS, San Juan, Puerto Rico
🇺🇸USC CRS, Los Angeles, California, United States
🇺🇸Univ. of Miami AIDS CRS, Miami, Florida, United States
Pilot Randomized Study of Paromomycin (Aminosidine) vs Streptomycin for Uncomplicated Pulmonary Tuberculosis
Not Applicable
Completed
- Conditions
- Tuberculosis, Pulmonary
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- FDA Office of Orphan Products Development
- Target Recruit Count
- 24
- Registration Number
- NCT00004444
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath